Brian Gormley

Investors and entrepreneurs will track decisions affecting drugs, medical devices and telehealth.

Venture capitalists and startups in reproductive health are scenario planning for how the U.S. presidential election could affect abortion services and other sectors in the field.

For a drugmaker advancing medicines through clinical trials, time is the enemy: the longer the process takes, the more costs rise. Newly formed Dash Bio says it has a solution. 

With its fourth fund, KdT will continue to make bets on startups that apply data, technology to healthcare and other sectors.

The company’s upsized offering is a hopeful sign for venture investors in the sector.

A legal requirement for an in-person doctor visit to receive a controlled substance was waived in the pandemic. The waiver expires at the end of this year, and telehealth companies are fighting to hang on to it.

The number of deals for $100 million or more have put biotech on pace to come close to full-year 2021’s record total, industry data show.

Exclusive | Medical-Robotics Startup Mendaera Raises $73 Million for Market Launch

The new firm is raising a $150 million fund to back startups around science emerging outside Boston and San Francisco.

The performance of newly public entrants in coming weeks will color other startups’ decisions on whether to take the plunge themselves.

Exclusive | Edge Medical Ventures Opens New Offices, Raises Capital Toward First Fund

Exclusive | EGenesis Raises $191 Million for Transplants of Genetically Edited Pig Organs

For decades cancer drugmakers have taken a more-is-more model when dosing drugs in clinical trials. U.S. regulators want them to reconsider that approach.

The firm connects patients with healthcare professionals who help them negotiate an increasingly complex medical system.

The firm connects patients with healthcare professionals who help them negotiate an increasingly complex medical system.

A noninvasive technology that uses sound waves to destroy tumors gets a tailwind from VC interest in late-stage medtechs.

Medical-device companies are raising big venture rounds to fortify their business and position themselves for a strong public offering or sale.

Medical-device companies are raising big venture rounds to fortify their business and position themselves for a strong public offering or sale.

2 days ago ... Israeli startup aims to compete with U.S. heart-pump pioneer Abiomed, now owned by Johnson & Johnson. But analysts say the market has lots ...

16 hours ago ... Biotechnology startups historically have relied on top pharmaceutical companies to make acquisition bids. Now a new class of buyers is ...